盐酸缬更昔洛韦片效果怎么样呢？

It is an antiviral drug produced by the Swiss company Roche. It is used to treat patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis, and to prevent CMV infection in high-risk solid organ transplant patients.

Valganciclovir hydrochloride tablets are sensitive to human viruses including human cytomegalovirus (HCMV), and valganciclovir hydrochloride tablets are sensitive to herpes simplex virus-1 and herpes simplex virus-2 (HSV-1, HSV-2), human herpesvirus-6, 7, 8 (HHV-6, 7, 8), Epstein-Barr virus, varicella-zoster virus (VZV) and hepatitis B virus. What is the therapeutic effect of Valganciclovir Hydrochloride Tablets? This is an issue that patients are more concerned about.

Clinical studies of valganciclovir hydrochloride tablets in AIDS patients infected with CMV retinitis have shown that valganciclovir hydrochloride tablets and intravenous ganciclovir are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to the valganciclovir hydrochloride tablet group or the intravenous ganciclovir group for induction therapy. The proportion of patients with progression of CMV retinitis at week 4 was the same in both groups. After induction therapy, both groups of patients in the study continued to receive maintenance therapy with valganciclovir hydrochloride tablets 900 mg per day. Among patients who received induction therapy with valganciclovir hydrochloride tablets or intravenous ganciclovir tablets followed by maintenance therapy with valganciclovir hydrochloride tablets, the mean (median) time from randomization to progression of CMV retinitis was: 226 (160) days and 219 (125) days.

The antiviral effect of valganciclovir hydrochloride tablets has been clinically confirmed by treating AIDS patients with newly diagnosed retinitis (clinical study WV15376). The detection rate of CMV virus decreased from 46% (32/69) to 7% (4/55) after 4 weeks of treatment with valganciclovir hydrochloride tablets, and the U.S. Food and Drug Administration (FDA) approved the increased use of valganciclovir hydrochloride tablets in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

The above is the therapeutic effect confirmed by the clinical research of Valganciclovir Hydrochloride Tablets provided by our medical companion overseas medical consulting service company. From this point of view, the therapeutic effect is very ideal.